Flavin-containing monooxygenase activity in hepatocytes and microsomes: In vitro characterization and in vivo scaling of benzydamine clearance

被引:22
作者
Fisher, MB [1 ]
Yoon, K [1 ]
Vaughn, ML [1 ]
Strelevitz, TJ [1 ]
Foti, RS [1 ]
机构
[1] Pfizer Inc, Pfizer Global Res & Dev, Dynam & Metab, Discovery Pharmacokinet, Groton, CT 06340 USA
关键词
D O I
10.1124/dmd.30.10.1087
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Liver microsomes, and more recently cryopreserved hepatocytes, are commonly used in the in vitro characterization of the metabolism of new xenobiotics. The flavin-containing monooxygenases (FMO) are a major nonP450 oxidase present in liver microsomes and hepatocytes. Since FMO is known to be thermally labile, and this enzyme may be involved in the metabolic clearance of some drugs, we sought to more completely characterize the metabolic competency of this enzyme in cryopreserved hepatocytes and in liver microsomes preincubated under various conditions using benzydamine as an in vitro and in vivo probe. The metabolism of benzydamine to its major metabolite, the N-oxide, is mediated by FMO3 in humans. We found that the in vitro microsomal t(1/2) was 70% longer when incubations were prewarmed at 37degreesC in the absence of NADPH compared with prewarming in the presence of an NADPH-regenerating system, and N-oxide formation was inhibited >99%. Interestingly, the in vivo clearance predicted from these incubations and from human hepatocytes overpredicted the observed clearance of benzydamine in humans (>10.5 versus 2.4 ml/min/kg). In contrast, rat hepatocytes successfully predicted rat in vivo benzydamine clearance to within similar to30% (>68 versus 48 ml/min/kg). Benzydamine N-oxidation in liver microsomes from all common preclinical species demonstrated heat sensitivity. This information should be considered when extrapolating metabolism data of xenobiotics from these in vitro systems.
引用
收藏
页码:1087 / 1093
页数:7
相关论文
共 30 条
[1]   METABOLISM OF THIORIDAZINE BY MICROSOMAL MONOOXYGENASES - RELATIVE ROLES OF P450 AND FLAVIN-CONTAINING MONOOXYGENASE [J].
BLAKE, BL ;
ROSE, RL ;
MAILMAN, RB ;
LEVI, PE ;
HODGSON, E .
XENOBIOTICA, 1995, 25 (04) :377-393
[2]  
Cashman JR, 1999, HANDBOOK OF DRUG METABOLISM, P477
[3]  
CHASSEAUD LF, 1985, INT J TISSUE REACT, V7, P195
[4]   Advances in in vitro drug metabolism screening [J].
Eddershaw, PJ ;
Dickins, M .
PHARMACEUTICAL SCIENCE & TECHNOLOGY TODAY, 1999, 2 (01) :13-19
[5]   ADME/PK as part of a rational approach to drug discovery [J].
Eddershaw, PJ ;
Beresford, AP ;
Bayliss, MK .
DRUG DISCOVERY TODAY, 2000, 5 (09) :409-414
[6]   Present and future in vitro approaches for drug metabolism [J].
Ekins, S ;
Ring, BJ ;
Grace, J ;
McRobie-Belle, DJ ;
Wrighton, SA .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2000, 44 (01) :313-324
[7]   A convenient method to discriminate between cytochrome P450 enzymes and flavin-containing monooxygenases in human liver microsomes [J].
Grothusen, A ;
Hardt, J ;
Brautigam, L ;
Lang, D ;
Bocker, R .
ARCHIVES OF TOXICOLOGY, 1996, 71 (1-2) :64-71
[8]  
Haining RL, 1997, DRUG METAB DISPOS, V25, P790
[9]  
Kalvass JC, 2001, DRUG METAB DISPOS, V29, P1332
[10]   AN ASSAY OF FLAVIN-CONTAINING MONOOXYGENASE ACTIVITY WITH BENZYDAMINE N-OXIDATION [J].
KAWAJI, A ;
OHARA, K ;
TAKABATAKE, E .
ANALYTICAL BIOCHEMISTRY, 1993, 214 (02) :409-412